H.B. Fuller Company Price & Performance (FUL)

Amundi has raised its stake in H.B. Fuller by an impressive 191.9% during Q4, now holding 28,553 shares valued at $1.8 million. This move underscores growing institutional interest, as other firms like Bank of New York Mellon and Wesbanco Bank have also expanded their positions in the specialty chemicals company.1

H.B. Fuller’s stock has fallen to a 52-week low of $54.18, reflecting a 31.5% drop over the year. Broader market challenges and industry-specific headwinds have weighed on its performance, though analysts maintain price targets between $60 and $73, signaling potential recovery.2

H.B. Fuller’s Q4 earnings of $0.92 per share missed forecasts, leading to analyst downgrades. JPMorgan and Citigroup cut price targets, while Deutsche Bank maintains a buy rating at a lower target. The stock’s outlook remains cautious amid competitive pressures and tariff concerns.3